| Since its founding in 2001, Genesis has developed unmatched expertise in the field of
mitochondria and mtDNA and has leveraged this expertise to create: - Immediate opportunities to enter the fast growing and highly profitable molecular diagnostic market with a significant pipeline of efficient, low cost, screening, diagnostic, and treatment monitoring capabilities
- Dramatic new insights into drug discovery, treatment pathways, and mitochondria function through a proprietary, novel, IP autonomous, unreported library of thousands of newly discovered mtDNA associated molecules
-
Significant future opportunities for differentiated diagnostic, therapeutic, and personalized healthcare products covering cancer, neurological disorders, diabetes, and other diseases through the full integration of Genesis’ technology with leading drug and diagnostic development platforms
Based on its encompassing core technology, Genesis Genomics has: - Launched mtDNA tests for: 1) assessing the genetic risk associated with ultraviolet radiation (‘UVR’) induced DNA damage, and 2) measuring the amount of DNA damage resulting from UVR exposure
- Developed tests which are ready to be commercialized for : 1) identifying false negatives in prostate biopsies through the detection of underlying molecular alterations in histologically normal tissue, and 2) assessing the protective and therapeutic efficacy of compounds targeting UVR induced DNA damage
- Created a robust pipeline of highly sensitive, highly specific biomarkers and tests - up to 96% AUC/ROC - for high burden disease conditions including lung, colorectal, breast, and prostate cancer and melanoma, all of which currently have limited early-stage, non-invasive alternatives; each representing a $10.0 billion plus market opportunity
|
